Perflubron as an oral contrast agent for MR imaging

Results of a phase III clinical trial

Robert F. Mattrey, Michael A. Trambert, Jeffrey J. Brown, Stuart W. Young, Jean Noel Bruneton, George E. Wesbey, Zubin N. Balsara

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

PURPOSE: To assess perflubron for magnetic resonance (MR) imaging in the abdomen and pelvis in a multicenter trial. MATERIALS AND METHODS: MR images were obtained in 127 subjects before and after ingestion of perflubron with T1-, proton-density-, and T2-weighted sequences at 0.38, 1.0, or 1.5 T. Postcontrast images were compared with baseline images, and percentage of additional bowel darkened, distinction of bowel from adjacent tissue, and change in image artifact were graded. RESULTS: Perflubron increased the bowel darkening in over 92% of subjects with all sequences and field strengths. It improved definition of the left lobe of the liver and body and tail of the pancreas in 67%, 29%, and 42% of subjects, respectively, and of the uterus and bladder in 80% and 76%. Abnormal tissue was more conspicuous in 69% of subjects. Highest scores were achieved when the upper abdomen was imaged 5- 30 minutes and the pelvis 10-40 minutes after ingestion. No image artifacts or side effects were attributed to perflubron. CONCLUSION: Perflubron is safe, and its efficacy was unaffected by pulse sequences, magnetic field strength, or time delay.

Original languageEnglish (US)
Pages (from-to)841-848
Number of pages8
JournalRadiology
Volume191
Issue number3
DOIs
StatePublished - Jan 1 1994

Fingerprint

Phase III Clinical Trials
Contrast Media
Magnetic Resonance Imaging
Pelvis
Abdomen
Artifacts
Eating
Magnetic Fields
Multicenter Studies
Uterus
Protons
Pancreas
Urinary Bladder
Magnetic Resonance Spectroscopy
perflubron
Liver

Keywords

  • Colon, MR
  • Intestines, MR
  • Liver, MR
  • Magnetic resonance (MR), contrast enhancement
  • Pancreas, MR
  • Stomach, MR

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Mattrey, R. F., Trambert, M. A., Brown, J. J., Young, S. W., Bruneton, J. N., Wesbey, G. E., & Balsara, Z. N. (1994). Perflubron as an oral contrast agent for MR imaging: Results of a phase III clinical trial. Radiology, 191(3), 841-848. https://doi.org/10.1148/radiology.191.3.8184076

Perflubron as an oral contrast agent for MR imaging : Results of a phase III clinical trial. / Mattrey, Robert F.; Trambert, Michael A.; Brown, Jeffrey J.; Young, Stuart W.; Bruneton, Jean Noel; Wesbey, George E.; Balsara, Zubin N.

In: Radiology, Vol. 191, No. 3, 01.01.1994, p. 841-848.

Research output: Contribution to journalArticle

Mattrey, RF, Trambert, MA, Brown, JJ, Young, SW, Bruneton, JN, Wesbey, GE & Balsara, ZN 1994, 'Perflubron as an oral contrast agent for MR imaging: Results of a phase III clinical trial', Radiology, vol. 191, no. 3, pp. 841-848. https://doi.org/10.1148/radiology.191.3.8184076
Mattrey, Robert F. ; Trambert, Michael A. ; Brown, Jeffrey J. ; Young, Stuart W. ; Bruneton, Jean Noel ; Wesbey, George E. ; Balsara, Zubin N. / Perflubron as an oral contrast agent for MR imaging : Results of a phase III clinical trial. In: Radiology. 1994 ; Vol. 191, No. 3. pp. 841-848.
@article{0c4d053a6af54959a4c4b8c87260b273,
title = "Perflubron as an oral contrast agent for MR imaging: Results of a phase III clinical trial",
abstract = "PURPOSE: To assess perflubron for magnetic resonance (MR) imaging in the abdomen and pelvis in a multicenter trial. MATERIALS AND METHODS: MR images were obtained in 127 subjects before and after ingestion of perflubron with T1-, proton-density-, and T2-weighted sequences at 0.38, 1.0, or 1.5 T. Postcontrast images were compared with baseline images, and percentage of additional bowel darkened, distinction of bowel from adjacent tissue, and change in image artifact were graded. RESULTS: Perflubron increased the bowel darkening in over 92{\%} of subjects with all sequences and field strengths. It improved definition of the left lobe of the liver and body and tail of the pancreas in 67{\%}, 29{\%}, and 42{\%} of subjects, respectively, and of the uterus and bladder in 80{\%} and 76{\%}. Abnormal tissue was more conspicuous in 69{\%} of subjects. Highest scores were achieved when the upper abdomen was imaged 5- 30 minutes and the pelvis 10-40 minutes after ingestion. No image artifacts or side effects were attributed to perflubron. CONCLUSION: Perflubron is safe, and its efficacy was unaffected by pulse sequences, magnetic field strength, or time delay.",
keywords = "Colon, MR, Intestines, MR, Liver, MR, Magnetic resonance (MR), contrast enhancement, Pancreas, MR, Stomach, MR",
author = "Mattrey, {Robert F.} and Trambert, {Michael A.} and Brown, {Jeffrey J.} and Young, {Stuart W.} and Bruneton, {Jean Noel} and Wesbey, {George E.} and Balsara, {Zubin N.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1148/radiology.191.3.8184076",
language = "English (US)",
volume = "191",
pages = "841--848",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Perflubron as an oral contrast agent for MR imaging

T2 - Results of a phase III clinical trial

AU - Mattrey, Robert F.

AU - Trambert, Michael A.

AU - Brown, Jeffrey J.

AU - Young, Stuart W.

AU - Bruneton, Jean Noel

AU - Wesbey, George E.

AU - Balsara, Zubin N.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - PURPOSE: To assess perflubron for magnetic resonance (MR) imaging in the abdomen and pelvis in a multicenter trial. MATERIALS AND METHODS: MR images were obtained in 127 subjects before and after ingestion of perflubron with T1-, proton-density-, and T2-weighted sequences at 0.38, 1.0, or 1.5 T. Postcontrast images were compared with baseline images, and percentage of additional bowel darkened, distinction of bowel from adjacent tissue, and change in image artifact were graded. RESULTS: Perflubron increased the bowel darkening in over 92% of subjects with all sequences and field strengths. It improved definition of the left lobe of the liver and body and tail of the pancreas in 67%, 29%, and 42% of subjects, respectively, and of the uterus and bladder in 80% and 76%. Abnormal tissue was more conspicuous in 69% of subjects. Highest scores were achieved when the upper abdomen was imaged 5- 30 minutes and the pelvis 10-40 minutes after ingestion. No image artifacts or side effects were attributed to perflubron. CONCLUSION: Perflubron is safe, and its efficacy was unaffected by pulse sequences, magnetic field strength, or time delay.

AB - PURPOSE: To assess perflubron for magnetic resonance (MR) imaging in the abdomen and pelvis in a multicenter trial. MATERIALS AND METHODS: MR images were obtained in 127 subjects before and after ingestion of perflubron with T1-, proton-density-, and T2-weighted sequences at 0.38, 1.0, or 1.5 T. Postcontrast images were compared with baseline images, and percentage of additional bowel darkened, distinction of bowel from adjacent tissue, and change in image artifact were graded. RESULTS: Perflubron increased the bowel darkening in over 92% of subjects with all sequences and field strengths. It improved definition of the left lobe of the liver and body and tail of the pancreas in 67%, 29%, and 42% of subjects, respectively, and of the uterus and bladder in 80% and 76%. Abnormal tissue was more conspicuous in 69% of subjects. Highest scores were achieved when the upper abdomen was imaged 5- 30 minutes and the pelvis 10-40 minutes after ingestion. No image artifacts or side effects were attributed to perflubron. CONCLUSION: Perflubron is safe, and its efficacy was unaffected by pulse sequences, magnetic field strength, or time delay.

KW - Colon, MR

KW - Intestines, MR

KW - Liver, MR

KW - Magnetic resonance (MR), contrast enhancement

KW - Pancreas, MR

KW - Stomach, MR

UR - http://www.scopus.com/inward/record.url?scp=0028364502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028364502&partnerID=8YFLogxK

U2 - 10.1148/radiology.191.3.8184076

DO - 10.1148/radiology.191.3.8184076

M3 - Article

VL - 191

SP - 841

EP - 848

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -